Novel therapeutics for cystic fibrosis

Marcus Mall (Berlin, Germany)

Source: ERS Webinar 2020: Novel therapeutics for cystic fibrosis
Number: 0
Disease area: -

WebcastPDF journal article, handout or slides

Rating: 5
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Marcus Mall (Berlin, Germany). Novel therapeutics for cystic fibrosis. ERS Webinar 2020: Novel therapeutics for cystic fibrosis

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

Sebnem Ozdogan - 12.01.2020 13:42
Well done
You must Login to comment this presentation.


Related content which might interest you:
Genotype-specific small-molecule therapy for cystic fibrosis
Source: Breathe 2013; 9: 176-186
Year: 2013


Genomically-guided therapies: a new era for cystic fibrosis
Source: Virtual Congress 2020 – European Reference Network for rare lung diseases (ERN-LUNG): acting for improved cross-border management of rare diseases
Year: 2020


Update on new treatments for cystic fibrosis
Source: Virtual Congress 2020 – Updates in cystic fibrosis
Year: 2020


Targeting CFTR as a therapy for cystic fibrosis
Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung
Year: 2010

New cystic fibrosis therapy targets
Source: Research Seminar 2014 - Protein quality control in lung disease
Year: 2014

Cystic fibrosis: prospects for therapy of some class 1 mutations
Source: Annual Congress 2007 - Cystic fibrosis: will the new biology deliver?
Year: 2007


Genotype specific therapies for cystic fibrosis
Source: Annual Congress 2004 - New approaches to cystic fibrosis: from cells and molecules to novel therapies
Year: 2004

Novel therapeutics for CF
Source: International Congress 2019 – Future of cystic fibrosis care: insights from the Lancet Commission
Year: 2019


New vaccines for use in cystic fibrosis
Source: Annual Congress 2004 - New approaches to cystic fibrosis: from cells and molecules to novel therapies
Year: 2004

Neomacrolides in cystic fibrosis
Source: Annual Congress 2012 - Non-antibiotic effects of macrolides in lung disease
Year: 2012


Potential therapeutic use of 12-Lipoxygenase inhibitors in the treatment of mucus overproduction in cystic fibrosis
Source: Research Seminar 2009 - Molecular and Cellular aspects of Chronic Lung Disease
Year: 2009

Formulation of dual modality nanoparticles to enhance tobramycin efficacy in cystic fibrosis
Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways
Year: 2013

Revisiting α1-antitrypsin therapy in cystic fibrosis: can it still offer promise?
Source: Eur Respir J 2007; 29: 229-230
Year: 2007


Lung inflammation in cystic fibrosis: an overlooked therapeutic target?
Source: Virtual Congress 2020 – Cystic fibrosis: from cradle to old age
Year: 2020


Novel protein biomarkers of bronchiectasis in children with cystic fibrosis
Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects
Year: 2014

Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology
Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung
Year: 2012

Transition in cystic fibrosis
Source: International Congress 2017 – PG16 Transition of children and adolescents into adult care
Year: 2017


CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways
Source: Eur Respir Rev, 29 (156) 190068; 10.1183/16000617.0068-2019
Year: 2020